Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The earliest amber from the Middle Devonian of China.

Science advances·2026

Same author

Radiomic Signature of the Substantia Nigra on Neuromelanin-Sensitive MRI Distinguishes Bipolar II Disorder From Unipolar Depression.

Brain and behavior·2026

Same author

A novel berberine derivative B12 exhibits superior anti-obesity effects via targeting brown and white adipocyte dynamics.

International journal of obesity (2005)·2026

Same author

Monitoring pneumonia onset and severe respiratory infectious diseases using quantitative computed tomography, validation amidst the coronavirus disease 2019 outbreak at the end of 2022 in the Chinese mainland.

Journal of thoracic disease·2026

Same author

Edaravone delivery of exosome-liposome hybrid nanoparticles for the treatment of ischemic stroke.

Materials today. Bio·2026

Same author

Gray matter volume and structural covariance alterations in young males with childhood-onset growth hormone deficiency.

BMC medical imaging·2026

Search research articles

Related Experiment Video

Updated: May 30, 2026

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope

Published on: March 24, 2017

Monoclonal antibody against NRP-1 b1b2.

Xiang Li¹, Fanghong Luo, Shengyu Wang

¹Cancer Research Center, Medical College, Xiamen University, 422 Siming South Road, Xiamen, Fujian, China.

Hybridoma (2005)

|August 20, 2011

Summary

Researchers developed a new monoclonal antibody targeting Neuropilin-1 (NRP-1) b1b2 domain. This antibody shows potential for cancer treatment strategies by targeting tumor cells expressing NRP-1.

More Related Videos

Generation of Monoclonal Antibodies Against Natural Products

Generation of Monoclonal Antibodies Against Natural Products

Published on: April 6, 2019

Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium

Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium

Published on: May 18, 2021

Related Experiment Videos

Last Updated: May 30, 2026

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope

Published on: March 24, 2017

Generation of Monoclonal Antibodies Against Natural Products

Generation of Monoclonal Antibodies Against Natural Products

Published on: April 6, 2019

Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium

Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium

Published on: May 18, 2021

Area of Science:

Biochemistry
Immunology
Oncology

Background:

Neuropilin-1 (NRP-1) is a protein crucial for angiogenesis, promoting endothelial cell activity by binding VEGF(165).
NRP-1 has a complex structure including extracellular domains (a1a2, b1b2, c), a transmembrane domain, and a cytoplasmic tail.

Purpose of the Study:

To establish a specific monoclonal antibody (MAb) targeting the b1b2 domain of Neuropilin-1.
To evaluate the utility of this MAb in detecting NRP-1 in cancer contexts.

Main Methods:

Hybridoma technology was employed to generate the monoclonal antibody.
Western blot analysis was used to confirm the antibody's specificity and binding capabilities.

Main Results:

A monoclonal antibody (clone A6-26-11-26) specific for the NRP-1 b1b2 domain was successfully established.
Western blot confirmed the MAb binds to both native NRP-1 b1b2 and NRP-1 derived from tumor cells.

Conclusions:

The developed monoclonal antibody against NRP-1 b1b2 is a valuable tool.
This antibody holds promise for advancing cancer target strategies and diagnostics.